International Stem Cell (ISCO) Gains from Investment Securities (2013 - 2020)
International Stem Cell (ISCO) posted quarterly Gains from Investment Securities of -$40000.0 for Q4 2020, down 119.32% year-over-year from $207000.0 in Q1 2020, and up 85.82% quarter-over-quarter from -$282000.0 in Q3 2020.
International Stem Cell (ISCO) Gains from Investment Securities (2013 - 2020) Analysis & Trends
International Stem Cell (ISCO) has reported Gains from Investment Securities for 8 consecutive years, with -$40000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Gains from Investment Securities fell 119.32% year-over-year to -$40000.0; the TTM figure through Dec 2020 stood at -$207000.0 (up 86.54% YoY), while the FY2020 annual figure was -$207000.0, up 86.54% from the prior year.
- Gains from Investment Securities improved to -$40000.0 in Q4 2020 per ISCO's latest filing, from -$282000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.6 million in Q1 2016 and bottomed at -$12.2 million in Q2 2016.
- Historically, Gains from Investment Securities has averaged -$832600.0 across 5 years, with a median of -$296500.0 in 2019.
- On a YoY basis, Gains from Investment Securities climbed as much as 487.33% in 2016 and fell as far as 1826.44% in 2016.
- International Stem Cell's Gains from Investment Securities stood at -$3.3 million in 2016, then soared by 83.38% to -$554000.0 in 2017, then jumped by 50.18% to -$276000.0 in 2018, then soared by 175.0% to $207000.0 in 2019, then plunged by 119.32% to -$40000.0 in 2020.
- Business Quant data shows ISCO's Gains from Investment Securities at -$40000.0 in Q4 2020, -$282000.0 in Q3 2020, and $225000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -40,000.00 |
| Dec 31, 2020 | -40,000.00 |
| Sep 30, 2020 | -282,000.00 |
| Sep 30, 2020 | -282,000.00 |
| Jun 30, 2020 | 225,000.00 |
| Jun 30, 2020 | 225,000.00 |
| Mar 31, 2020 | -110,000.00 |
| Mar 31, 2020 | -110,000.00 |
| Dec 31, 2019 | 207,000.00 |
| Dec 31, 2019 | 207,000.00 |
| Sep 30, 2019 | -837,000.00 |
| Sep 30, 2019 | -837,000.00 |
| Jun 30, 2019 | -311,000.00 |
| Jun 30, 2019 | -311,000.00 |
| Mar 31, 2019 | -597,000.00 |
| Mar 31, 2019 | -597,000.00 |
| Dec 31, 2018 | -276,000.00 |
| Dec 31, 2018 | -276,000.00 |
| Sep 30, 2018 | -758,000.00 |
| Sep 30, 2018 | -758,000.00 |